Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal Meningitis
Open Access
- 21 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 53 (10), 1019-1023
- https://doi.org/10.1093/cid/cir613
Abstract
Background. Many deaths from cryptococcal meningitis (CM) may be preventable through early diagnosis and treatment. An inexpensive point-of-care (POC) assay for use with urine or a drop of blood would facilitate early diagnosis of cryptococcal infection in resource-limited settings. We compared cryptococcal antigen (CRAG) concentrations in plasma, serum, and urine from patients with CM, using an antigen-capture assay for glucuronoxylomannan (GXM) and a novel POC dipstick test. Methods. GXM concentrations were determined in paired serum, plasma, and urine from 62 patients with active or recent CM, using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). A dipstick lateral-flow assay developed using the same monoclonal antibodies for the sandwich ELISA was tested in parallel. Correlation coefficients were calculated using Spearman rank test. Results. All patients had detectable GXM in serum, plasma, and urine using the quantitative ELISA. Comparison of paired serum and plasma showed identical results. There were strong correlations between GXM levels in serum/urine (rs = 0.86; P < .001) and plasma/urine (rs = 0.85; P < .001). Levels of GXM were 22-fold lower in urine than in serum/plasma. The dipstick test was positive in serum, plasma, and urine in 61 of 62 patients. Dipstick titers correlated strongly with ELISA. Correlations between the methods were 0.93 (P < .001) for serum, 0.94 (P < .001) for plasma, and 0.94 (P < .001) for urine. Conclusions. This novel dipstick test has the potential to markedly improve early diagnosis of CM in many settings, enabling testing of urine in patients presenting to health care facilities in which lumbar puncture, or even blood sampling, is not feasible.This publication has 19 references indexed in Scilit:
- Monoclonal Antibodies Specific for Immunorecessive Epitopes of Glucuronoxylomannan, the Major Capsular Polysaccharide of Cryptococcus neoformans, Reduce Serotype Bias in an Immunoassay for Cryptococcal AntigenClinical and Vaccine Immunology, 2011
- Cryptococcal Antigen Screening for Patients Initiating Antiretroviral Therapy: Time for ActionClinical Infectious Diseases, 2010
- Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South AfricaJournal of Infection, 2010
- Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programmeAIDS, 2010
- Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected casesBMC Infectious Diseases, 2010
- Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South AfricaClinical Infectious Diseases, 2009
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2008
- Monoclonal Antibodies Reactive with Immunorecessive Epitopes of Glucuronoxylomannan, the Major Capsular Polysaccharide ofCryptococcus neoformansClinical and Vaccine Immunology, 2003
- Cryptococcal antigen detection from the urine of AIDS patientsDiagnostic Microbiology and Infectious Disease, 1993